Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $12.83

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received an average rating of “Hold” from the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $12.83.

A number of equities analysts have recently issued reports on SAGE shares. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. JPMorgan Chase & Co. cut their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Truist Financial lowered their price objective on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. Wedbush dropped their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Wednesday, October 9th. Finally, Bank of America reduced their target price on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a report on Wednesday, October 9th.

Sage Therapeutics Stock Up 2.1 %

Shares of NASDAQ SAGE opened at $5.28 on Friday. The firm’s 50-day moving average price is $6.70 and its 200-day moving average price is $9.00. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $28.26. The company has a market cap of $322.98 million, a PE ratio of -0.93 and a beta of 0.92.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter last year, the company earned ($2.81) EPS. The firm’s revenue for the quarter was up 337.1% on a year-over-year basis. As a group, equities research analysts anticipate that Sage Therapeutics will post -6.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock valued at $107,781,000 after acquiring an additional 432,013 shares in the last quarter. RTW Investments LP grew its position in shares of Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after purchasing an additional 111,123 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Sage Therapeutics by 27.1% in the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after purchasing an additional 952,193 shares during the last quarter. State Street Corp lifted its position in shares of Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after buying an additional 451,377 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.